Tranexamic Acid

CHEMBL877 Phase 4 ได้รับการอนุมัติ Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

157.2 g/mol

LogP

-2.0

Phase

4

Tranexamic acid is a synthetic lysine analog that competitively inhibits plasminogen activation by blocking the lysine-binding sites on plasminogen and plasmin, preventing fibrinolysis and stabilizing clot formation. It is used to reduce bleeding in surgical procedures (particularly orthopedic and cardiac surgery), heavy menstrual bleeding, trauma-associated hemorrhage, and hereditary angioedema. Its antifibrinolytic mechanism makes it widely applicable in conditions where excessive plasmin-mediated clot dissolution contributes to bleeding.

น้ำหนักโมเลกุล

157.2100 g/mol

LogP

-2.00

TPSA

63.30 Å²

Lipinski RO5

ผ่าน

ด้านการรักษา

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Benign Prostatic Hyperplasia Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Asthma Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Melanoma Inflammatory Bowel Disease Chronic Kidney Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Hypertension Breast Cancer Chronic Pain Heart Failure Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure

Embed this structure

SMILES

NC[C@H]1CC[C@H](C(=O)O)CC1

InChI

InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-

Molecular Formula

C8H15NO2

HBD / HBA

2 / 3

พันธะที่หมุนได้

2

อะตอมหนัก

11

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Tranexamic acid is a synthetic lysine analog that competitively inhibits plasminogen activation by blocking the lysine-binding sites on plasminogen and plasmin, preventing fibrinolysis and stabilizing clot formation. It is used to reduce bleeding in surgical procedures (particularly orthopedic and cardiac surgery), heavy menstrual bleeding, trauma-associated hemorrhage, and hereditary angioedema. Its antifibrinolytic mechanism makes it widely applicable in conditions where excessive plasmin-mediated clot dissolution contributes to bleeding.

Yes, Tranexamic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL877. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5526. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Tranexamic Acid บน PillFYI

โครงสร้าง

ข้อมูลด่วน

สูตร: C8H15NO2
คำพ้องความหมาย: 7

ลิงก์ภายนอก

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.